Duchenne Muscular Dystrophy News and Research

RSS
Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that causes the loss of both muscle function and independence. DMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children).
New cell-based technologies could help improve understanding of muscle-wasting disease

New cell-based technologies could help improve understanding of muscle-wasting disease

Mapping the Genes Responsible for Pluripotency

Mapping the Genes Responsible for Pluripotency

BU postdoctoral researcher wins competitive NIH Pathway to Independence Award

BU postdoctoral researcher wins competitive NIH Pathway to Independence Award

MSU students develop exoskeleton app for patient with Duchenne muscular dystrophy

MSU students develop exoskeleton app for patient with Duchenne muscular dystrophy

Research establishes use of chimeric cells as potential therapy for Duchenne muscular dystrophy

Research establishes use of chimeric cells as potential therapy for Duchenne muscular dystrophy

New guidelines intend to provide template for optimal, most up-to-date DMD care

New guidelines intend to provide template for optimal, most up-to-date DMD care

Plymouth researcher receives grant to further investigate causes of hereditary neuro-tumors

Plymouth researcher receives grant to further investigate causes of hereditary neuro-tumors

Cell therapy for heart disease caused by muscular dystrophy also improves limb strength, study shows

Cell therapy for heart disease caused by muscular dystrophy also improves limb strength, study shows

New CRISPR gene-editing technique can correct majority of mutations that cause DMD

New CRISPR gene-editing technique can correct majority of mutations that cause DMD

Scientists create artificial human muscles

Scientists create artificial human muscles

FDA chief says he’s open to rethinking incentives on orphan drugs

FDA chief says he’s open to rethinking incentives on orphan drugs

Researchers discover how high glucose levels in pregnancy affect baby's heart

Researchers discover how high glucose levels in pregnancy affect baby's heart

SLU scientists provide promising approach in designing new drugs for DMD

SLU scientists provide promising approach in designing new drugs for DMD

UT Southwestern researchers develop improved gene-editing technique to correct DMD mutations

UT Southwestern researchers develop improved gene-editing technique to correct DMD mutations

New initiative aims to improve chances of medicines receiving positive HTA decisions

New initiative aims to improve chances of medicines receiving positive HTA decisions

Clinical trial results could lead to treatment of heart disease in Duchenne muscular dystrophy patients

Clinical trial results could lead to treatment of heart disease in Duchenne muscular dystrophy patients

Study identifies predictors of poor outcomes in Duchenne muscular dystrophy patients

Study identifies predictors of poor outcomes in Duchenne muscular dystrophy patients

CRISPR-Gold corrects gene mutations in mice with Duchenne muscular dystrophy

CRISPR-Gold corrects gene mutations in mice with Duchenne muscular dystrophy

University Of Minnesota scientists describe breakthrough in research related to FSHD

University Of Minnesota scientists describe breakthrough in research related to FSHD

Penn researchers find abnormally shortened telomeres in young DMD patients’ muscle stem cells

Penn researchers find abnormally shortened telomeres in young DMD patients’ muscle stem cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.